Acadia's Nuplazid rebounds in schizophrenia with study win

Investigators hope their research will lead to sensor systems that connect biology to electronic circuits.
Acadia said it would launch a second trial for Nuplazid in the first half of 2020. (Pixabay)

Acadia's Nuplazid suffered a big loss in July after a late-stage trial as an add-on treatment for schizophrenia fell flat. But that study wasn't Nuplazid's last go at the indication, and now a phase 2 win could help Acadia get over the top. 

Nuplazid added to standard-of-care antipsychotics bested antipsychotics alone in reducing the negative symptoms of schizophrenia after 26 weeks in patients with controlled positive symptoms, according to top-line data from Acadia's phase 2 Advance study. 

Acadia said it would launch a second pivotal study for the 34-milligram dose of Nuplazid in the first half of 2020, with additional results from the Advance study set to be presented at a future medical meeting.

“The positive efficacy results and favorable tolerability profile of (Nuplazid) observed in the Advance study represent an important step forward for patients and their families, given the lack of currently approved treatment options for the negative symptoms of schizophrenia,” Acadia President Serge Stankovic said in a release.

RELATED: Acadia's Nuplazid flops schizophrenia trial on the heels of DOJ marketing probe

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.